Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706423 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8586304 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL420278 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL17493340 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2228073 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL1548302 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL2227363 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL3116850 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL22963142 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL28730 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0320960-B1 | AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-05-12 | — | — | EP | claimed |
| US-5145848-A | AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1992-09-08 | — | — | US | claimed |
| EP-0396588-A1 | AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1990-11-14 | — | — | EP | claimed |
| WO-1989005815-A1 | AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1989-06-29 | — | — | WO | claimed |
| EP-0320960-A1 | Amino anthracenediones-bis platinum complexes, useful as antitumoral agents | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1989-06-21 | — | — | EP | claimed |
| WO-2024058984-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2015091643-A1 | BIOLOGICAL CULTURE OF A STRAIN OF THE SPECIES PSEUDOMONAS GRAMINIS AND USE OF SAID CULTURE AS ANTAGONIST FOR THE BIOCONTROL OF PATHOGENIC BACTERIA | UNIVERSITAT DE LLEIDA (ES) | 2015-06-25 | — | — | WO | disclosed |
| US-8148321-B2 | Bioconjugates as therapeutic agent and synthesis thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2009-04-02 | — | — | US | disclosed |
| EP-1996236-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | National Institute of Immunology (IN) | 2008-12-03 | — | — | EP | disclosed |
| EP-1876914-A2 | LIGNAN-CONTAINING COMPOSITIONS | Archer-Daniels-Midland Company (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007108013-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2007-09-27 | — | — | WO | disclosed |
| WO-2005079764-A1 | COMPOSITIONS AND METHODS FOR TIMED RELEASE OF WATER-SOLUBLE NUTRITIONAL SUPPLEMENTS | OSMOPHARM USA (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005056525-A2 | DEACETYLATION OF N-ACETYLGLUCOSAMINE | BIO-TECHNICAL RESOURCES (US) | 2005-06-23 | — | — | WO | disclosed |
| US-6242583-B1 | COUPLING CARBOHYDRATE COMPOUNDS IN PRESENCE OF PROMOTER TO A FUNCTIONALIZED SOLID SUPPORT | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-05 | — | — | US | disclosed |
| US-5622693-A | WATER SOLUBLE, FREEZE DRIED, SOLID MIXTURE OF POLYOXYETHYLENE GLYCOL AND A THICKENER OR HUMECTANT; HEAT RESISTANCE, SKIN FEEL | SHISEIDO COMPANY LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| EP-0320960-B1 | AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-05-12 | — | — | EP | disclosed |
| US-5145848-A | AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1992-09-08 | — | — | US | disclosed |
| EP-0412449-A2 | Solid cosmetic composition | SHISEIDO COMPANY LIMITED (JP) | 1991-02-13 | — | — | EP | disclosed |
| EP-0320960-A1 | Amino anthracenediones-bis platinum complexes, useful as antitumoral agents | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | DNPEP, LNPEP, RNPEP | LMNA 1551/4885L3MBTL1 1253/4885TDP1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.